Search Results

You are looking at 1 - 10 of 173 items for :

  • Refine by Access: All content x
Clear All
Free access

Belinda van Zyl, Denise Tang, and Nikola A Bowden

, we review biomarkers of platinum chemotherapy resistance in ovarian cancer with a focus on biomarkers that are potentially targetable for future treatment combinations. Ovarian cancer subtypes There are 2 major subtypes of ovarian cancer that

Free access

Cristina L Ronchi, Silviu Sbiera, Luitgard Kraus, Sebastian Wortmann, Sarah Johanssen, Patrick Adam, Holger S Willenberg, Stefanie Hahner, Bruno Allolio, and Martin Fassnacht

et al . 2005 ). Platinum compounds exert their cytotoxic effects by binding to DNA and forming DNA adducts leading to interstrand or intrastrand cross links that disrupt the structure of the DNA molecule. These changes eventually trigger apoptosis and

Free access

Pasqualino Malandrino, Abir Al Ghuzlan, Marine Castaing, Jacques Young, Bernard Caillou, Jean-Paul Travagli, Dominique Elias, Thierry de Baere, Clarisse Dromain, Angelo Paci, Philippe Chanson, Martin Schlumberger, Sophie Leboulleux, and Eric Baudin

objective responses but their impact on survival is still debated ( Gicquel et al . 1997 , Allolio & Fassnacht 2006 , Phan 2007 , Fareau et al . 2008 , Veytsman et al . 2009 ). Multiagent chemotherapy combining platinum with doxorubicin–etoposide or

Free access

O Hentic, P Hammel, A Couvelard, V Rebours, M Zappa, M Palazzo, F Maire, G Goujon, A Gillet, P Lévy, and P Ruszniewski

World Health Organization (WHO) 2010 classification ( Rindi et al . 2010 ). Etoposide–platinum combination is the gold standard for NECs grade 3, with a major antitumoral activity and high tumor response rates (41–67%) reported in the main series

Open access

Alessandra Mangone, Barbara Altieri, Mario Detomas, Alessandro Prete, Haider Abbas, Miriam Asia, Yasir S Elhassan, Giovanna Mantovani, and Cristina L Ronchi

.02.034 ) Laufs V Altieri B Sbiera S Kircher S Steinhauer S Beuschlein F Quinkler M Willenberg HS Rosenwald A Fassnacht M 2018 ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas . European Journal of

Free access

Céline Van Themsche, Sophie Parent, Valérie Leblanc, Caroline Descôteaux, Anne-Marie Simard, Gervais Bérubé, and Eric Asselin

, and stops cell proliferation leading to apoptosis ( Wang & Lippard 2005 ). The absence of selectivity of platinum-based drugs for cancer cells, however, results in severe side effects ( Kelland 2007 ). The use of 17β-oestradiol (E 2 ) as a carrier

Free access

Michael G Apps, Eugene H Y Choi, and Nial J Wheate

they are able to bind and disrupt the function of DNA. Despite a claim that 50–70% of all patients receive a platinum drug ( Sava & Dyson 2006 ), which has been repeated by others ( Harper et al . 2010 , Zalba & Garrido 2013 ), there is no evidence on

Free access

Louis de Mestier, Angela Lamarca, Jorge Hernando, Wouter Zandee, Teresa Alonso-Gordoa, Marine Perrier, Annemiek ME Walenkamp, Bipasha Chakrabarty, Stefania Landolfi, Marie-Louise F Van Velthuysen, Gursah Kats-Ugurlu, Alejandra Caminoa, Maxime Ronot, Prakash Manoharan, Alejandro Garcia-Alvarez, Tessa Brabander, María Isabel García Gómez-Muriel, Guillaume Cadiot, Anne Couvelard, Jaume Capdevila, Marianne E Pavel, and Jérôme Cros

therapeutic options have been increasing over the last decade ( Pavel et al. 2016 ), the etoposide-platinum chemotherapy (CT) combination has long been the reference therapy for G3 NENs (regardless of morphology) based on the assumption that their clinical

Free access

Biao Wan, Leheyi Dai, Li Wang, Ying Zhang, Hong Huang, Guanhua Qian, and Tinghe Yu

Introduction Ovarian cancer has a high response rate (>80%) to the initially platinum-based chemotherapy; however, the majority of cases will gradually become refractory and eventually lead to treatment failure ( Bookman 2012 , Li et al

Free access

Wei-Chun Chang, Hsiao-Ching Wang, Wei-Chung Cheng, Juan-Cheng Yang, Wei-Min Chung, Yen-Pin Ho, Lumin Chen, Yao-Ching Hung, and Wen-Lung Ma

Introduction Platinum-based adjuvant chemotherapy is widely used in the management of patients with solid tumors, including gynecological malignancies ( Lawrie et al. 2015 , Falcetta et al. 2016 ), gut cancers ( Malka et al. 2014